Larazotide (AT-1001): The Structure of an Octapeptide Zonulin Antagonist

Most peptides in the research world go by a short code. Larazotide hands you something more useful: an eight-letter fingerprint, GGVLVQPG, that tells you almost everything about what it is. Read that string correctly and the whole compound comes into view — a small synthetic chain copied from a bacterial toxin, then repurposed to do the exact opposite of what the toxin does. Larazotide, and the research-grade material sold under the code AT-1001, is offered for research use only and is not for human or animal consumption. With that framing in place, this piece walks through the structure of larazotide acetate: how its octapeptide sequence reads, where the sequence came from, how researchers describe its zonulin-antagonist mechanism, and how the peptide gets built and modified in the lab.

Reading the Octapeptide Sequence

The quickest way to understand larazotide is to read it one residue at a time — because the whole molecule is just eight amino acids strung together.

The sequence, letter by letter

In single-letter code, larazotide is GGVLVQPG. Spelled out in the three-letter convention chemists use, that is Gly-Gly-Val-Leu-Val-Gln-Pro-Gly: glycine, glycine, valine, leucine, valine, glutamine, proline, glycine. Each letter is one amino acid, and since there are exactly eight of them, larazotide counts as an octapeptide. If you've ever looked at another eight-residue octapeptide, the counting logic is identical — "octa" simply names how many residues sit in the chain.

Two features of the sequence reward a second look. Glycine bookends the chain and turns up three times overall; it's the smallest amino acid, and it hands the backbone extra flexibility. Then there's a proline in the seventh position. Proline carries an unusual ring structure that locks part of the backbone, so it tends to introduce a bend or turn rather than let the chain run straight. That detail matters later, because the way this peptide folds is central to how it's thought to bind. Underneath all of it are the amide bonds that link each residue — the same peptide-bond chemistry that holds every protein together.

Formula and size

Put the eight residues together and the molecular formula works out to C₃₂H₅₅N₉O₁₀, with a molecular weight of roughly 725.85 g/mol. That's a modest size for a peptide — small enough to synthesize cleanly, large enough to carry a specific shape. The "acetate" in larazotide acetate points to the acetate salt form the compound is usually handled as, not to any change in the peptide sequence itself.

From a Cholera Toxin to a Zonulin Mimetic

Here's the part that makes the structure interesting: the sequence wasn't designed from a blank sheet. It was lifted from a bacterial toxin and then turned against that toxin's own job.

Zonula occludens toxin

The cells lining your gut are sealed to one another by structures called tight junctions — picture the grout between floor tiles, controlling what slips through the gaps rather than passing through the cells themselves. Vibrio cholerae, the bacterium behind cholera, secretes a protein called zonula occludens toxin (ZOT) that pries those junctions open. Researchers studying ZOT identified an eight-amino-acid stretch with a sequence analogous to a portion of that toxin, and it overlapped with the pathway used by a human protein named zonulin — the body's own regulator of tight-junction permeability.

Why copy a toxin at all

The clever move was to copy the fragment but flip its function. Where the toxin's job is to open junctions, the synthetic octapeptide is studied as something that competes at the same zonulin pathway and blocks the opening signal instead. That's why the compound draws research interest from the field of gut-barrier biology — the study of what happens when the intestinal lining turns more permeable than it should. Naming that area early helps explain the attention: researchers care about larazotide because barrier integrity sits at the center of many inflammation questions, not because of any claim about what it does in a person.

How It Works: Zonulin Antagonism and Tight Junctions

In plain terms, the research picture is this: in laboratory models, larazotide helps keep the junctions between cells assembled rather than letting them loosen.

The zonulin pathway

Zonulin raises the permeability of epithelial and endothelial barriers by loosening tight junctions, and that loosening has been documented across a range of inflammatory conditions. The literature describes larazotide as a zonulin antagonist that modulates this pathway to reduce paracellular permeability — the uncontrolled passage of molecules through the gaps between cells rather than through them. In cultured intestinal epithelial monolayers, larazotide has been reported to enhance tight-junction assembly and barrier function and to reduce gliadin-induced permeability responses. Every bit of that is an observation from cell-culture and animal research — not a statement about outcomes in people.

What the structure does when it binds

Here's where the shape of the peptide comes back. In molecular-modeling studies, larazotide adopts what researchers call a "global turn" conformation when it settles into its binding site — the chain folds back on itself rather than lying flat, which lines up with that proline-driven bend noted earlier. Within the sequence, a GVL motif (glycine-valine-leucine) has been singled out as central to the peptide's binding interactions. So the structure isn't incidental to the function — the specific residues, and the turn they create, are what let the molecule engage its target in these models.

How the Peptide Is Built and Modified

For all its clever origin story, larazotide is manufactured the way most research peptides are: one amino acid at a time, anchored to a solid support.

Fmoc solid-phase synthesis

Published work describes building the octapeptide by microwave-assisted Fmoc solid-phase peptide synthesis, starting from an Fmoc-glycine Wang resin and adding each protected residue in turn before cleaving the finished chain from the resin. Want the step-by-step version of that chemistry? The linked walkthrough covers the same Fmoc-to-cleavage sequence used here.

Structure-activity tweaks

Because the sequence is short, it makes a convenient system for asking which residues actually matter. Researchers have built capped and truncated derivatives of larazotide — including a shortened fragment written as Ac-GVLV-NHCH₃ that retained activity comparable to the parent octapeptide. That result points straight back at the GVL motif: if you can trim much of the chain and keep the core intact, the structure is telling you where the function lives. This kind of structure-activity mapping is how a peptide's essential fingerprint gets narrowed down.

Where the Research Interest Sits

Interest in larazotide clusters around barrier integrity as a shared theme rather than any single disease. A review of the compound catalogued zonulin-pathway modulation studied across celiac disease, type 1 diabetes, inflammatory bowel disease, and respiratory injury, and separate work has tied zonulin-driven gut permeability to inflammatory processes elsewhere in the body. All of it sits at the in-vitro and animal-model level.

On the clinical side, precision matters. Larazotide advanced into Phase 3 trials for celiac disease, but 9 Meters Biopharma announced in 2022 that it would discontinue that Phase 3 program, and the compound remains investigational. It is not an approved drug. Research-grade larazotide handled in a laboratory is not equivalent to any FDA-approved pharmaceutical product, and nothing about its structure changes the fact that it's supplied strictly for research use.

Frequently Asked Questions

What is the amino acid sequence of larazotide (AT-1001)?

In single-letter code, larazotide is GGVLVQPG — glycine-glycine-valine-leucine-valine-glutamine-proline-glycine. That's eight residues, which is why it's called an octapeptide. Its molecular formula is C₃₂H₅₅N₉O₁₀ and its molecular weight is roughly 725.85 g/mol.

What does "zonulin antagonist" mean?

Zonulin is a human protein that loosens the tight junctions between intestinal cells, increasing paracellular permeability. A zonulin antagonist like larazotide occupies the same signaling pathway and, in research models, blocks that loosening so the junctions stay assembled. The literature describes it as a tight-junction regulator studied in cell-culture and animal systems, not as a compound acting on a consumer.

Where did the larazotide sequence come from?

The eight-residue sequence was derived from a fragment of the Vibrio cholerae zonula occludens toxin (ZOT), a bacterial enterotoxin that opens tight junctions. Researchers noticed the fragment overlapped with the human zonulin pathway and rebuilt it as a synthetic peptide studied as a blocker of that pathway rather than a trigger of it.

Is larazotide an FDA-approved drug?

No. Larazotide reached Phase 3 clinical trials for celiac disease, but 9 Meters Biopharma discontinued that Phase 3 program in 2022. It remains an investigational compound. Research-grade larazotide sold for laboratory use is not equivalent to any FDA-approved pharmaceutical product and is for research use only.

The Bottom Line

With larazotide, the structure really is the story. Eight residues — GGVLVQPG — borrowed from a cholera-toxin fragment, folded by a proline-driven turn, and studied as a molecule that competes at the zonulin pathway to keep tight junctions assembled in laboratory models. The structure-activity work on truncated fragments shows the field is still mapping exactly which residues carry that function, which is part of what keeps a small peptide like this interesting to read at the chemical level. To go deeper on the chemistry underneath it, the walkthroughs on solid-phase peptide synthesis and the peptide bond itself are the natural next reads.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.